Microchip Biology (688321.SH): Application for clinical trial of CS231295 tablets for the treatment of advanced solid tumors was accepted

Zhitongcaijing · 10/17 10:17

Zhitong Finance App News, Microchip Biotech (688321.SH) issued an announcement. The company and its wholly-owned subsidiary Shenzhen Microchip Pharmaceutical Co., Ltd. recently received a “Notice of Acceptance” issued by the State Drug Administration for registered clinical trials of domestically produced drugs, and the clinical trial application for CS231295 tablets to treat advanced solid tumors was accepted.

According to reports, CS231295 is a small-molecule multi-target protein kinase inhibitor. Pre-clinical research results showed that CS231295 showed remarkable pharmacodynamic activity, ideal pharmacokinetic characteristics, and good safety. CS231295 not only has synthetic lethal effects and targeted efficacy on tumors carrying specific cancer suppressor gene defects, but also has remarkable anti-tumor angiogenic effects, and can achieve a broad spectrum of anti-tumor activity. At the same time, CS231295 also has good blood-brain barrier permeability, and also has obvious treatment advantages for primary and metastatic brain tumors. In particular, it has good application potential in the treatment of malignant brain tumors and tumor brain metastases, and is expected to provide differentiated innovative treatment plans for various tumors.